Table 3 Clinical outcomes
Clinical Outcome | Results |
|---|---|
Number of exacerbations, median (range) | 2 (0,13) |
Age at study completion in years, median (range) | 3.7 (2.2–7.1) |
Brasfield chest x-ray scores, enrollment | 21.5 (18.0,25.0) |
Brasfield chest x-ray scores, study completion | 21.0 (17.0,24.0) |
Change in chest x-ray scores, n = 25, median (range) | −0.5 (−3.0, 4.0)* |
Culture results, n = subjects with positive culture at any time over two-year study period, (%) | |
Staphylococcus aureus | 26 (87%) |
Pseudomonas aeruginosa | 4 (13%) |
Haemophilus influenzae | 29 (97%) |
Stenotrophomonas maltophilia | 4 (13%) |
PEx Culture results, n = positive culture during PEx, (% of PEx) [# subjects with positive culture] | |
Staphyloccus aureus | 37 (39%) [18] |
Pseudomonas aeruginosa | 2 (2%) [2] |
Haemophilus influenzae | 27 (28%) [15] |
Stenotrophomonas maltophilia | 4 (4%) [3] |
Change in weight z-score, n = 28, median (range) | 0.39 (−2.00, 1.61) * |
FEV1 percent predicted at 7 years, n = 23, median (range) | 104 (89–138) |